Characteristic | Ruxolitinib (n = 68) | BAT (n = 192) | p |
---|---|---|---|
Demographics | |||
Mean age (95% CI), years | 66.8 (65.1 to 68.5) | 59.1 (57.7 to 61.3) | < 0.001 |
Male sex, % | 57 | 48 | 0.205 |
Clinical parameters | |||
IPSS risk status, % | 0.001 | ||
High risk | 57 | 15 | |
Intermediate-2 | 31 | 16 | |
Intermediate-1 | 12 | 39 | |
Low risk | 0 | 30 | |
Mean spleen size (95% CI), cma | 19.6 (18.4 to 21.6) | 3.6 (3.0 to 4.2) | 0.001 |
Mean hemoglobin (95% CI), g/dL | 10.8 (10.3 to 11.3) | 12.1 (11.7 to 12.5) | 0.001 |
Mean platelet count (95% CI), × 109/L | 401.4 (341.0 to 462.9) | 521.1 (464.6 to 577.5) | 0.015 |
Mean WBC count (95% CI), ×109/L | 17.7 (14.2 to 21.3) | 13.4 (11.6 to 15.3) | 0.021 |
Mean peripheral blasts (95% CI), % | 0.8 (0.5 to 1.1) | 0.5 (0.3 to 0.7) | 0.097 |
WHO grade of BM fibrosisb, % | |||
Grade 1 | 22 | 37 | 0.098 |
Grade 2 | 53 | 52 | |
Grade 3 | 25 | 11 |